BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...
New long-term clinical data for BioNTech's personalized mRNA cancer vaccine has delivered a potentially paradigm-shifting result in one of oncology's most challenging diseases. Presented at the ...
Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.
German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating German ...
BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results